Emerging studies indicate that DNA damage in
cancer cells triggers antitumor immunity, but its intrinsic regulatory mechanism in
breast cancer cells remains poorly understood. Here, we show that ZMYND8 is upregulated and inhibits micronucleus formation and DNA damage in
breast cancer cells. Loss of ZMYND8 triggered activation of the
DNA sensor
cyclic guanosine monophosphate-adenosine monophosphate synthase in micronuclei, leading to further activation of the downstream signaling effectors stimulator of IFN genes and NF-κB, but not TANK-binding
kinase 1 and
IFN regulatory factor 3, thereby inducing the expression of IFNβ and IFN-stimulated genes (ISG) in
breast cancer cells in vitro and
tumors in vivo. ZMYND8 knockout (KO) in
breast cancer cells promoted infiltration of CD4+ and CD8+ T cells, leading to
tumor inhibition in syngeneic mouse models, which was significantly attenuated by treatment of anti-CD4/CD8-depleting
antibodies or anti-IFNAR1 antibody and in immunodeficient Rag1 KO mice. In human
breast tumors, ZMYND8 was negatively correlated with ISGs, CD4, CD8A, CD8B, and the
tumor-lymphocyte infiltration phenotype. Collectively, these findings demonstrate that maintenance of
genome stability by ZMYND8 causes
breast cancer cells to evade cytotoxic T-lymphocyte surveillance, which leads to
tumor growth. SIGNIFICANCE: These findings show that ZMYND8 is a new negative and intrinsic regulator of the innate immune response in
breast tumor cells, and ZMYND8 may be a possible target for antitumor
immunotherapy.